779 results on '"Pohlman, Brad"'
Search Results
2. Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation
3. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
4. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
5. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
6. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation
7. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study
8. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
9. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
10. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times–Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
11. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer
12. Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
13. Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
14. Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
15. Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
16. Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study
17. The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
18. Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma
19. Synergistic Effect of Major Histocompatibility Complex Class I–Related Chain A and Human Leukocyte Antigen–DPB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation
20. Impact of comorbidities on outcomes of elderly patients with diffuse large B‐cell lymphoma
21. Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
22. The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma
23. Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
24. Nonmyeloablative Second Transplants are Associated with Lower Nonrelapse Mortality and Superior Survival Than Myeloablative Second Transplants
25. Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy
26. Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma
27. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
28. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome
29. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma
30. Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma
31. Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel
32. Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience
33. 250 - Evaluation of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Utility of Baseline Cardiac Biomarkers
34. Clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences
35. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation
36. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
37. Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation
38. Advance Care Planning in Hematopoietic Stem Cell Transplant Recipients: A Survey of Providers in a Blood & Marrow Transplant Program
39. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome in the Contemporary Era
40. The Impact of Clinical Pharmacists in Hematopoietic Stem Cell Transplant (HSCT) Outpatient Clinic at an Academic Medical Center
41. Measuring Patient-Reported Outcomes (PROs) in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients
42. Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
43. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
44. Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)
45. Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status
46. A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma
47. Validation of the mantle cell lymphoma international prognostic index: A single-center retrospective analysis
48. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia
49. Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma
50. 529 - The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.